AI Biomarker Services

Quantitative Continuous Scoring


Tailored precision analytics for the next generation 
of antibody-drug conjugates (ADCs)

Contact Us to Learn More

Antibody-Drug Conjugates (ADCs) rely on precise target binding and internalization. While traditional immunohistochemistry (IHC) scoring provides a snapshot of target expression, it often fails to capture the granular, spatial, and subcellular nuances that determine ADC efficacy.

BioAI’s Quantitative Continuous Scoring (QCS) service bridges this gap, providing biopharma customers with high-resolution, continuous data to refine patient selection and de-risk ADC development.

 

The Challenges with conventional IHC Scoring

Traditional visual scoring of IHC, for instance H-Score or 0/1+/2+/3+, is:

  • Over-simplified – Fixed categories hide the real continuum of antigen expression.
  • Subjective – Results vary significantly between observers.
  • Incomplete – They often miss critical spatial details and subcellular localization (membrane vs. cytoplasm), which directly affects payload delivery.

BioAI’s customized Solutions for Quantitative Continuous Scoring

We work closely with your translational and clinical teams to develop bespoke QCS models 
tailored to your specific molecule:

  1. Predictive Biomarker Discovery: Use QCS data to establish “Continuous Cut-points” that maximize 
    Progression-Free Survival (PFS) and Objective Response Rate (ORR) in clinical trials.
  2. Clinical Patient Stratification: Identify “Ultra-Low” 
expressors or specific spatial patterns that correlate with 
    clinical response, effectively expanding your eligible 
patient population beyond traditional IHC cut-offs.

Our customized QCS solutions provide a granular understanding of your target’s 
expression and distribution across the entire tumor landscape.

Core Capabilities

  • Subcellular Spatial Profiling by quantifying antigen expression specifically on the cell membrane versus the cytoplasm - a critical metric for ADCs undergoing active internalization.
  • Normalized Membrane Ratio (NMR) by calculating precise membrane-to-cytoplasm ratios.
  • Granular Intensity Distribution: Move from 4-tier categories to a continuous customized range, capturing e.g. low-expressors that may still benefit from next generation, high-potency ADCs.
  • Heterogeneity Mapping: Quantify the spatial "clustering" of target expression to predict the potential for Bystander Effects and overall tumor response.

Why partnering with BioAI on your QCS needs?

  • Multimodal Integration: Our QCS solutions can be integrated with our broader biomarker prediction and genomic profiling from H&E for a holistic view of the tumor microenvironment.
  • Interdisciplinary Expertise: Our team of board-certified pathologists and ML engineers ensure that every algorithm is biologically grounded and clinically relevant.
  • Speed & Scalability: Process thousands of Whole Slide Images (WSI) with consistent, reproducible results, moving your program from data read to insight in hours, not days